

## 4DMEDICAL ADVANCES AUSTRALIAN CLINICAL PILOT WITH I-MED RADIOLOGY NETWORK

### Highlights

- Successful completion of Phase One of 4DMedical's clinical pilot program with Australia's leading medical imaging provider, I-MED Radiology Network (I-MED)
- Phase One provided I-MED radiologists with the ability to use XV Lung Ventilation Analysis Software (XV LVAS™) in patient settings to provide insights into patient care
- Phase One received overwhelmingly positive feedback from I-MED radiologists and patients
- XV LVAS applied various respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, sarcoidosis, silicosis and long COVID
- Phase Two will be completed over the remaining year to assess a potential commercial partnership

**1 September 2021:** 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company"), a medical technology company focused on commercialising its FDA-cleared and TGA-approved respiratory imaging platform, is pleased to announce an agreement to commence Phase Two of its clinical pilot program with I-MED Radiology Network (I-MED), following the successful completion of Phase One in Victoria, Australia.

I-MED is Australia's largest outsourced provider of radiology, with more than 200 clinics nationwide, offering a range of diagnostic imaging services to private and public hospitals.

Phase One of the clinical pilot was conducted at an I-MED imaging clinic in Melbourne, where patients were referred an XV Lung Ventilation Analysis Software (XV LVAS™) scan. 4DMedical's ASX announcement on the 18 December 2020 referred to a preliminary commercial assessment with I-MED, after which the Phase One program commenced on a confidential basis. The XV LVAS scans were successfully generated using existing imaging infrastructure and provided doctors with greater insight into the patients' lung health.

Valuable insights and important learnings were gained, following the input of I-MED specialist thoracic radiologists who were engaged to review and utilise XV LVAS reports as part of the clinical workflow. Disease indications analysed using XV LVAS during Phase One included asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, sarcoidosis, silicosis and long COVID (a term that describes persistent symptoms following COVID infection).

Having confirmed the compatibility with I-MED's imaging infrastructure, the clinical pilot will now move into Phase Two and will allow additional radiologists to become familiar with XV LVAS' application. Phase Two will be completed in a different Australian state over the remainder of the year to further assess a potential commercial partnership with I-MED.

**I-MED General Manager Government Relations & External Partnerships, Mark Simpson, said:**

"Patients involved in the Phase One pilot overwhelmingly reported a positive experience. Beyond the technical success of the program, this important comfort and compliance metric shows we can adopt such transformative technologies without detriment to patient satisfaction, sustaining our ongoing commitment to outstanding patient care."

## 4DMedical Founder and CEO, Andreas Fouras, said:

"We are very excited to be conducting a clinical pilot with I-MED – a leader of pioneering new medical imaging technologies – to provide doctors and patients with improved insight into their lung health. Phase One of the clinical pilot was an overwhelming success with radiologists and patients reporting strong positive feedback. Although the partnership is not generating revenue at this stage, we aim to secure a commercial XV LVAS contract with I-MED provided that Phase Two is successful."

## ENDS

Authorised by the 4DMedical Board of Directors.

### Contacts:

<i>Corporate</i>	<i>Investor</i>	<i>Media</i>
Charlene Stahr	Simon Hinsley	Matthew Wright
Company Secretary	+ 61 401 809 653	+ 61 451 896 420
companysecretary@4dmedical.com	shinsley@4dmedical.com	matt@nwrcommunications.com.au

### About 4DMedical:

Based in Melbourne, Australia and Los Angeles, U.S., 4DMedical was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.